Clinical Trials Logo

Pneumococcal Disease clinical trials

View clinical trials related to Pneumococcal Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06182124 Recruiting - Clinical trials for Pneumococcal Disease

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

Start date: December 20, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults. This vaccine can possibly provide protection against further pneumococcal disease. This study will happen in in 2 stages: Stage 1 is seeking participants who are between 18 years to 49 years of age. The participants will receive 1 of 2 pneumococcal vaccine candidates (different formulations) or 20vPnC (Prevnar 20) as a single shot given into the upper arm muscle. Stage 2 will begin after participants have completed Stage 1, and a pneumococcal vaccine candidate has been decided. Stage 2 is seeking participants who are adults 50 years of age and older. The participants will receive the chosen pneumococcal vaccine candidate from Stage 1 or 20vPnC (Prevnar 20). The vaccines will be given as a single shot into the upper arm muscle. Participants will take part in this study for about 6 months for Stage 1 and 12 months for Stage 2. During this time participants will have from 2 to 4 clinic visits and 1 phone visit. At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during these clinic visits.

NCT ID: NCT06044077 Recruiting - Clinical trials for Pneumococcal Disease

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

Start date: September 8, 2023
Phase: Phase 3
Study type: Interventional

This study is a randomized, blinded, parallel controlled phase 3 clinical trial to evaluate the immunogenicity and safety of the 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and above.